{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:46:48Z","timestamp":1761518808551,"version":"build-2065373602"},"reference-count":34,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2005,10,5]],"date-time":"2005-10-05T00:00:00Z","timestamp":1128470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2005,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Inferences about the variations in the biology of breast carcinoma between African\u2010Americans and Caucasians have been reported. The difference in the prevalence of positive HER\u20102\/<jats:italic>neu<\/jats:italic> breast carcinoma was evaluated and the race\u2010specific risk was assessed for positive HER\u20102\/<jats:italic>neu<\/jats:italic> among a cohort of women diagnosed with their first primary breast carcinoma, given the accepted prognostic pathologic indicators for positive HER\u20102\/<jats:italic>neu<\/jats:italic> status.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Demographic, clinical, and pathologic data were collected from existing databases. The status of HER\u20102\/<jats:italic>neu<\/jats:italic> was considered positive if the immunohistochemistry score was 3<jats:sup>+<\/jats:sup> or if the fluorescent in situ hybridization indicated a ratio greater than 2. Multivariable logistic regression was used to determine the race\u2010specific risk for HER\u20102\/<jats:italic>neu<\/jats:italic> positive breast carcinoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The difference in the prevalence of HER\u20102\/<jats:italic>neu<\/jats:italic>\u2010positive status between African\u2010American and Caucasian women was not statistically significant (<jats:italic>P<\/jats:italic> = 0.46). For Caucasian women the likelihood for positive HER\u20102\/<jats:italic>neu<\/jats:italic> was statistically significant and increased almost linearly within each stage with nuclear grade dedifferentiation relative to the reference group, women with Stage 1, Grade 1 carcinomas. For African\u2010American women, this risk was not significantly associated with stage, nuclear grade, their interaction term, or other pathologic prognostic indicators.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The findings suggest that race modifies the association between the pathologic prognostic indicators of breast carcinoma and the likelihood of HER\u20102\/<jats:italic>neu<\/jats:italic>\u2010positive carcinoma. So far, clinical correlative studies of HER\u20102\/<jats:italic>neu<\/jats:italic> have not included race as an independent variable. Concerns about the limited generalizability and the need for validation of the findings across racial lines have been expressed previously. Cancer 2005. \u00a9 2005 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21463","type":"journal-article","created":{"date-parts":[[2005,10,5]],"date-time":"2005-10-05T16:47:56Z","timestamp":1128530876000},"page":"2189-2196","source":"Crossref","is-referenced-by-count":14,"title":["Race modifies the association between breast carcinoma pathologic prognostic indicators and the positive status for HER\u20102\/<i>neu<\/i>"],"prefix":"10.1002","volume":"104","author":[{"given":"Azadeh T.","family":"Stark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Claud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alissa","family":"Kapke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Linden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Griggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,10,5]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1340"},{"key":"e_1_2_5_4_2","first-page":"520","article-title":"Prognostic significance of HER\u20102\/neu positive breast carcinoma as a particular subset with peculiar clinical behavior","volume":"8","author":"Tetu B","year":"2002","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.10.2702"},{"key":"e_1_2_5_6_2","first-page":"1577","article-title":"Chemotherapy response of breast cancer depends on Her\u20102 status and anthracycline dose intensity in the neoadjuvant setting","volume":"7","author":"Petit T","year":"2001","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_7_2","first-page":"349","article-title":"Significance of, and optimal screening for, Her\u20102 gene amplification and protein overexpression in breast carcinoma","volume":"31","author":"Funkhouser WK","year":"2001","journal-title":"Ann Clin Lab Sci."},{"key":"e_1_2_5_8_2","first-page":"827","article-title":"Evaluation of the HER\u20102\/neu (erbB\u20102) status in breast cancer: from bench to bedside","volume":"12","author":"Hanna W","year":"1999","journal-title":"Med Pathol."},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970701)80:1<80::AID-CNCR11>3.0.CO;2-B"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.50.1.50"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11028"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10575"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<114::AID-CNCR16>3.0.CO;2-J"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015220420400"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960415)77:8<1465::AID-CNCR7>3.0.CO;2-B"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.77.3.351"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10827"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880215)61:4<758::AID-CNCR2820610421>3.0.CO;2-T"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10639"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950715)76:2<268::AID-CNCR2820760217>3.0.CO;2-1"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.9.705"},{"volume-title":"Applied logistic regression","year":"1997","author":"Hosmer D","key":"e_1_2_5_22_2"},{"key":"e_1_2_5_23_2","first-page":"1021","article-title":"Prognostic value of plasma HER\u20102\/neu in African\u2010American and Hispanic women with breast cancer","volume":"14","author":"Wu Y","year":"1999","journal-title":"Int J Oncol."},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.2.142"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11828"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980401)82:7<1310::AID-CNCR14>3.0.CO;2-9"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11604"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025481505537"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20279"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20500"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10274"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.7.471"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a117718"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.22.2720"},{"key":"e_1_2_5_35_2","unstructured":"National Institutes of Health. http:\/\/www4.od.nih.gov\/orwh\/revitalization.pdf [accessed Nov 15 2004]."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21463","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:30:27Z","timestamp":1760297427000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,5]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,11,15]]}},"alternative-id":["10.1002\/cncr.21463"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21463","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2005,10,5]]}}}